Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Array Biopharma Inc (ARRY)

14.17 0.08 (0.57%)

04-23 16:00

Open:

14.15

Pre. Close:

14.09

High:

14.48

Low:

14.05

Volume:

1,585,912

Market Cap:

2942M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

14.487 - 14.574

14.574 - 14.658

Low:

13.845 - 13.947

13.947 - 14.045

Close:

14.014 - 14.164

14.164 - 14.307

Technical analysis  (as of: 2018-04-23 4:27:11 PM)

Overall:

      

Stoxline posted a SELL today, upgraded from strong sell. But this stock still is very strong for short side. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell as long as the BUY warning is not issued.

Target:

Six months: 18.84     One year: 20.35

Support:

Support1: 14.05    Support2: 11.69

Resistance:

Resistance1: 16.13    Resistance2: 17.42

Pivot:

14.99

Moving Averages:

MA(5): 14.70     MA(20): 15.30

MA(100): 14.79     MA(250): 11.60

MACD:

MACD(12,26): -0.56     Signal(12,26,9): -0.48

%K %D:

%K(14,3): 4.10     %D(3): 16.39

RSI:

RSI(14): 38.09

52-Week:

High: 18.78  Low: 6.73  Change(%): 60.8

Average Vol(K):

3-Month: 324303  10-Days 218012

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
ARRY has closed above bottom band by 10.6%. Bollinger Bands are 19.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-04-17T11:46:21-04:00
JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position

2018-04-10T01:35:52-04:00
JF's Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New Position

2018-04-05T06:47:07-04:00
By The Numbers: Best Biotech Stocks

2018-04-03T13:10:52-04:00
JF's Core Biotech Buys #9: Shire In Play, Volatility Continues And Capitalizing On Weakness

2018-03-26T15:30:55-04:00
JF's Core Biotech Buys #8: Taking Advantage Of Volatility And Initiating A Position In Dynavax

2018-03-22T09:00:00-04:00
Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology

2018-03-20T12:01:06-04:00
Biotechs Approaching New Waters

2018-03-20T07:40:36-04:00
JF's Core Biotech Buys Edition 1 Volume 7: Updates And Taking Advantage Of Current Weakness

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

207.64

Shares Float (M)

204.54

% Held by Insiders

1.50

% Held by Institutions

99.40

Shares Short (K)

13633

Shares Short Prior Month (K)

21960

Stock Financials

EPS

-0.740

EPS Est. Current Year

-0.990

EPS Est. Next Year

-0.390

EPS Est. Next Quarter

-0.230

Forward EPS

-0.570

Book Value (p.s.)

12.380

PEG Ratio

-1.64

Profit Margin

Operating Margin

-236.60

Return on Assets (ttm)

-37.3

Return on Equity (ttm)

-93.1

Qtrly Rev. Growth

19.6

Gross Profit (p.s.)

0.338

Sales Per Share

EBITDA (p.s.)

-0.437

Qtrly Earnings Growth

Operating Cash Flow (M)

-67.32

Levered Free Cash Flow (M)

-37.43

atoplab.com

Valuation

P/E

-19.15

P/E Growth Ratio

0.01

P/BV

1.14

P/S

10508066816.00

P/CF

-43.70

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.